IDiyas

For the Inventor, By the Inventor

Scotch Plains, NJ, United States of America

Richard N Ingram

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 72(Granted Patents)


Location History:

  • Scotch Plains, NJ (US) (1997 - 2014)
  • Kenilworth, NJ (US) (2017)

Company Filing History:

goldMedal8 out of 1,829 
 
Schering Corporation
 patents
silverMedal3 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 1997-2017

Loading Chart...
Loading Chart...
11 patents (USPTO):
1. 9809648 - Engineered anti-IL-23p19 antibodies (2017-11-07),
2. 8710188 - Factor IXa crystals, related complexes and methods (2014-04-29),
3. 8513389 - Engineered anti-IL-23p19 antibodies (2013-08-20),
4. 8206943 - Assay for PCSK9 inhibitors (2012-06-26),
5. 7968683 - Factor IXa crystals, related complexes and methods (2011-06-28),
6. 7824897 - Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof (2010-11-02),
7. 7807160 - Engineered anti-IL-23 antibodies (2010-10-05),
8. 7700753 - Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof (2010-04-20),
9. 7529628 - Methods for identifying modified tumor necrosis factor-alpha converting enzyme inhibitors (2009-05-05),
10. 7138264 - Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof (2006-11-21),
11. 5632988 - Polypeptide inhibitors of gamma interferon (1997-05-27),

Title: The Innovations of Richard N Ingram

Introduction

Richard N Ingram is a notable inventor based in Scotch Plains, NJ (US), recognized for his contributions to the field of biotechnology. With a total of 11 patents to his name, Ingram has made significant advancements in medical treatments and therapeutic applications.

Latest Patents

Among his latest patents, Ingram has developed engineered anti-IL-23p19 antibodies. These engineered antibodies target human IL-23p19 and are intended for use in treating inflammatory, autoimmune, and proliferative disorders. Another significant invention is related to factor IXa crystals and their associated complexes. This patent focuses on methods for identifying inhibitors of factor IXa, which plays a crucial role in blood coagulation.

Career Highlights

Ingram has had a distinguished career, working with prominent companies such as Schering Corporation and Merck Sharp & Dohme Corporation. His work in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Ingram has collaborated with notable professionals in his field, including Brian M Beyer and Peter Orth. These partnerships have further enhanced his innovative capabilities and expanded the impact of his inventions.

Conclusion

Richard N Ingram's work exemplifies the spirit of innovation in biotechnology. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…